查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2011834

数位疗法市场：2026-2032年全球市场预测（依产品类型、治疗领域、平台、通路类型、最终用户和部署模式划分）

Digital Therapeutics Market by Product Type, Therapy Area, Platform, Channel Type, End User, Deployment Mode - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年数位疗法市场价值 56.1 亿美元，预计到 2025 年将成长至 64.1 亿美元，复合年增长率为 15.72%，到 2032 年将达到 180.5 亿美元。

主要市场统计数据
基准年 2024 56.1亿美元
预计年份：2025年 64.1亿美元
预测年份 2032 180.5亿美元
复合年增长率 (%) 15.72%

相关人员主导的趋势正在重新定义数位疗法，并重塑技术、证据和商业模式的临床实施。

数位疗法已成为一类基于实证医学的医疗介入手段，透过软体实现疾病的预防、管理或治疗。这些干预措施结合了临床最佳实践、监管监督和真实世界数据的收集，从而创造治疗价值，补充甚至在某些情况下取代传统的药物疗法和医疗设备疗法。该领域的发展趋势体现在技术的快速创新、某些司法管辖区监管规定的逐步明确，以及越来越多的保险公司和医疗服务提供者寻求可衡量的疗效和具有成本效益的治疗路径。

技术、监管政策的澄清以及不断变化的商业性奖励如何共同作用，重塑临床和企业相关人员的采取路径？

数位疗法领域正经历着一场变革性的转型，其驱动力来自多方面因素：软体介入技术的进步、远距远端医疗技术的日益普及以及越来越多的临床疗效证据。科技的成熟使得感测器整合更加强大，穿戴式装置具备更完善的远端监测功能，从而加强了患者生成数据与临床决策之间的连结。同时，虚拟实境和身临其境型体验正成为復健和心理健康领域差异化的治疗方式，为行为改变和治疗参与开闢了新的途径。

评估 2025 年新收费系统对硬体依赖型解决方案、采购经济和供应链策略的广泛和累积影响。

2025年新关税的实施将对数位疗法生态系统产生复杂的影响，其累积效应将波及供应链、设备供应和营运成本。依赖硬体的解决方案，尤其是那些整合穿戴装置、感测器和专用周边设备的解决方案，如果零件和成品均需缴纳进口关税，则将面临更高的投入成本。这些成本压力可能会蔓延至远端监测套件和捆绑式疾病管理解决方案，导致价格上涨，迫使开发人员重新思考筹资策略和产品配置。

基于细分的详细见解，确定每个治疗领域、交付模式和实施方法的临床、技术和商业性重点。

市场区隔洞察揭示了不同的机会领域和风险因素，这些都需要精准的打入市场策略。基于治疗领域，临床重点包括心血管疾病（如心律不整、心臟衰竭和高血压）；糖尿病亚型（如妊娠糖尿病、1 型糖尿病和第 2 型糖尿病）；精神健康领域（如焦虑症、忧郁症、创伤后压力乳癌(PTSD) 和压力管理）；神经系统疾病（如气喘、慢性阻塞性肺病每个治疗领域都有其独特的证据标准、患者依从性模式和临床医生工作流程，这些都会影响产品设计和监管路径。

将各地区的市场动态进行比较，并透过针对美洲、欧洲、中东和非洲以及亚太市场的个人化方法，提供商业化的实用见解。

区域趋势导致监管、报销和部署环境存在差异，进而影响策略重点。在美洲，市场驱动因素包括支付方的参与、雇主主导的健康计画以及重视行动和云端干预措施的、具备技术素养的患者群体。虽然某些司法管辖区的监管清晰性为临床有效性检验和报销提供了明确的途径，但州和支付方层面的政策差异使得必须制定针对当地决策者的、具有针对性的证据。

透过跨通路临床检验、互通性和适应性经营模式，制定竞争和伙伴关係策略，使领导者脱颖而出。

主要企业之间的竞争格局由一系列策略塑造而成，这些策略强调临床检验、平台扩充性以及与整个医疗生态系统建立策略伙伴关係。市场领导优先进行随机对照试验和产生真实世界数据 (RWE)，以满足支付方和医疗服务提供者的期望，同时投资于互通性和应用程式介面 (API)，以实现与电子健康记录 (EHR) 和远端监测系统的整合。与医疗设备製造商、感测器供应商和专科诊所的伙伴关係，能够加快疾病特异性解决方案的上市速度，并支援提供全面的医疗服务。

在不断变化的市场环境中，开发人员和企业相关人员在加速采用和保护利润率方面面临的实际策略挑战和优先事项。

产业领导者应制定一系列切实可行的优先事项，协调产品开发、证据产生和商业性执行。首先，投资稳健的临床项目，包括随机对照试验和可操作的真实世界研究，这些研究应针对特定的治疗领域，例如心血管疾病亚型、糖尿病患者群体、神经系统疾病、辅助性治疗和呼吸系统疾病。其次，建构可跨云端和本地部署的模组化解决方案，以满足企业对资料主权和延迟敏感型工作流程的多样化需求。

采用透明的混合方法研究途径，将第二手资料与关键相关人员的检验结合，可以产生可操作和可复製的策略见解。

本研究采用混合方法，整合了全面的二手资料研究和与关键相关人员的直接沟通，以验证研究结果并阐明行业趋势。二手资料分析整合了监管检验、同行评审的临床文献、技术能力报告以及公开发布的合作关係和产品公告，以揭示不断演变的行业趋势。一手资料研究包括对临床医生、保险公司、企业健康管理专案经理、技术架构师和企业高管进行结构化访谈，以确定推动技术应用、采购挑战以及对证据的期望。

综合结论强调临床有效性、互通性和商业性灵活性是数位疗法永续发展的重要支柱。

数位疗法如今已成为临床护理和软体创新之间的策略性交汇点，为不断扩展的治疗领域和交付模式提供可扩展的、循证的干预措施。该领域的短期发展趋势将取决于企业能否证明其临床疗效，能否使商业模式与买家预期相符，以及能否适应影响硬体依赖型解决方案的宏观经济因素，例如关税。与临床工作流程的整合、互通性以及对真实世界数据的关注，对于将试点部署发展成为获得资助的大规模计画至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 数位疗法市场：依产品类型划分

  • 无需处方笺/非处方（OTC）数位药物
  • 处方笺数位药物（PDTx）

第九章：按治疗领域分類的数位疗法市场

  • 糖尿病管理
  • 神经系统疾病
    • 忧郁症
    • 焦虑症
    • 思觉失调症
    • 癫痫
    • 多发性硬化症
  • 肥胖和体重管理
  • 慢性呼吸系统疾病
  • 心血管疾病
  • 心理和行为健康
  • 肌肉骨骼疾病/疼痛管理
  • 癌症支持护理
  • 消化系统疾病
  • 禁止抽烟
  • 女性健康
  • 復健和物理治疗
  • 物质使用障碍
  • 睡眠障碍

第十章 数位疗法市场：依平台划分

  • 智慧型手机应用程式
  • 穿戴式装置整合 DTx
  • 基于人工智慧/机器学习的数位疗法
  • 基于虚拟实境（VR）的数位化治疗
  • 数位监控+回馈系统
  • 网路/跨平台的治疗

第十一章 按通路类型分類的数位疗法市场

  • 病人/直接面向消费者 (D2C)
  • 医疗服务提供者（医院和诊所）
  • 雇主/公司的健康计划
  • 与製药公司合作
  • 政府和公共卫生系统

第十二章 数字疗法市场：依最终用户划分

  • 病人
  • 医护人员
  • 雇主和企业健康
  • 看护者及復健中心

第十三章 数位疗法市场：依部署模式划分

  • 基于云端的
  • 现场
  • 混合实现

第十四章 数位疗法市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 数位疗法市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 数位疗法市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国数位疗法市场

第十八章：中国数字疗法市场

第十九章 竞争情势

  • 2024年市场集中度分析
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2024 年
  • 2024年产品系列分析
  • 基准分析，2024 年
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • Noom, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Omada Health, Inc.
  • Otsuka Holdings Co., Ltd.
  • ResMed, Inc.
  • Teladoc Health, Inc.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-431752EA4722

The Digital Therapeutics Market was valued at USD 5.61 billion in 2024 and is projected to grow to USD 6.41 billion in 2025, with a CAGR of 15.72%, reaching USD 18.05 billion by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.61 billion
Estimated Year [2025] USD 6.41 billion
Forecast Year [2032] USD 18.05 billion
CAGR (%) 15.72%

Defining digital therapeutics and the stakeholder-driven dynamics reshaping clinical adoption across technology, evidence, and commercial models

Digital therapeutics have emerged as an evidence-driven category of medical interventions delivered through software to prevent, manage, or treat medical conditions. These interventions bridge clinical best practices, regulatory oversight, and real-world data capture to create therapeutic value that complements or, in some instances, substitutes traditional pharmacologic and device-based care. The landscape is defined by rapid technological innovation, increased regulatory clarity in some jurisdictions, and rising adoption among payers and providers seeking measurable outcomes and cost-effective care pathways.

Stakeholders across the ecosystem bring distinct priorities to adoption. Developers emphasize clinical validation, interoperability, and scalable architectures that support cloud and on-premise deployment models. Healthcare providers focus on integration into care pathways and workflow compatibility with clinician roles such as physicians, nurses, and therapists. Employers and payers increasingly evaluate digital therapeutics for chronic condition management and wellness programs, while patients seek user-friendly mobile and web experiences that respect privacy and demonstrate clinical benefit. Delivery modes span cloud, desktop, mobile, virtual reality, and web platforms, and application areas include disease management, rehabilitation, remote monitoring with sensor integration and wearable devices, as well as wellness management.

Consequently, decision makers must balance clinical evidence generation with product usability, regulatory compliance, and commercial models such as licensing, pay-per-use, and subscription structures that can be offered on annual or monthly terms. As adoption accelerates, convergence between health data ecosystems and consumer technologies creates new opportunities and challenges for scalability, reimbursement, and sustained engagement.

How technology, regulatory clarity, and shifting commercial incentives are converging to reshape adoption pathways across clinical and enterprise stakeholders

The digital therapeutics landscape is undergoing transformative shifts driven by converging forces: advances in software-based interventions, greater acceptance of telehealth modalities, and an expanding evidence base demonstrating clinical efficacy. Technology maturation has enabled more robust sensor integration and wearable devices that enhance remote monitoring capabilities, thereby strengthening the bridge between patient-generated data and clinician decision-making. Simultaneously, virtual reality and immersive experiences are emerging as differentiated delivery options for rehabilitation and mental health applications, creating new pathways for behavioral change and therapeutic engagement.

Regulatory evolution and payer receptivity are redefining market access. Clearer pathways for clinical validation and reimbursement are enabling higher-value procurement by healthcare providers, employers, and payers, but they also raise the bar for proof of outcomes and long-term adherence. Pricing models are shifting from one-time licensing to more outcome-oriented subscription structures and pay-per-use arrangements that align incentives between developers and purchasers. Meanwhile, integration imperatives drive enterprise architectures toward hybrid deployment models, balancing cloud scalability with on-premise requirements for data sovereignty and latency-sensitive workloads.

Finally, therapeutic focus is broadening beyond mental health and diabetes into neurology, oncology adjuncts, respiratory disease management, and cardiovascular subsegments such as arrhythmia and heart failure. This diversification increases the importance of tailored clinical pathways, interoperability with electronic health records, and partnerships between digital-native firms and traditional healthcare organizations to accelerate adoption and deliver measurable patient benefit.

Assessing the wide-ranging cumulative effects of new 2025 tariffs on hardware-dependent solutions, procurement economics, and supply chain strategies

The introduction of new tariffs in 2025 presents complex implications for the digital therapeutics ecosystem, with cumulative effects that extend across supply chains, device availability, and operating costs. Hardware-dependent solutions, particularly those incorporating wearable devices, sensors, and specialized peripherals, face increased input costs when components or finished devices are subject to import duties. These cost pressures can cascade into higher prices for remote monitoring kits and bundled disease management solutions, creating a need for developers to reassess sourcing strategies and product configurations.

Service delivery is also affected indirectly. Increased costs for physical devices may change adoption decisions among employers, payers, and patients, incentivizing greater reliance on software-only modalities such as mobile apps and cloud-delivered interventions. At the same time, tariffs can influence the competitive dynamics between domestic manufacturers and international suppliers, prompting greater investment in local manufacturing or alternative component procurement to maintain margins. Cloud-based services might be insulated from hardware levies but could face secondary impacts through changes in enterprise procurement and total cost of ownership calculations.

Regulatory and contractual frameworks will increasingly reflect these economic shifts. Providers and purchasers may renegotiate service agreements, extend device lifecycles through firmware updates and software enhancements, or prioritize interoperable solutions that reduce dependency on proprietary hardware. In the near term, stakeholders should model scenario analyses to understand how tariff-induced cost changes influence pricing strategies, reimbursement negotiations, and product roadmaps, while exploring mitigation through design simplification, regional supply diversification, and closer alignment with clinical stakeholders who value outcome-based payment structures.

Deep segmentation-driven insights identifying differentiated clinical, technological, and commercial priorities across therapeutic areas delivery modes and deployment choices

Segmentation insights reveal differentiated opportunity zones and risk vectors that demand precise go-to-market strategies. Based on therapeutic area, clinical focus ranges across cardiovascular conditions including arrhythmia, heart failure, and hypertension; diabetes subtypes such as gestational, type 1, and type 2; mental health areas encompassing anxiety disorders, depression, posttraumatic stress disorder, and stress management; neurology indications including epilepsy, multiple sclerosis, and Parkinson's disease; oncology subsegments like breast cancer, leukemia, and lung cancer; and respiratory conditions such as asthma and chronic obstructive pulmonary disease. Each therapeutic area exhibits unique evidence thresholds, patient adherence patterns, and clinician workflows that influence product design and regulatory pathways.

Delivery mode segmentation differentiates solutions by platform characteristics including cloud, desktop, mobile, virtual reality, and web. Cloud and mobile formats excel in scalability and patient engagement, whereas desktop and on-premise arrangements can be preferable for enterprise integration and data control. Virtual reality presents distinct value in rehabilitation and mental health modalities where immersive engagement drives therapeutic response. End user segmentation underscores adoption drivers across employers, healthcare providers, patients, and payers, with healthcare providers further divided into nurses, physicians, and therapists who each bring different clinical priorities and usability constraints. Application-based segmentation covers disease management, rehabilitation, remote monitoring with sensor integration and wearable devices, and wellness management, highlighting that remote monitoring requires strong interoperability and secure data pipelines for clinical decision support.

Distribution channels vary between direct approaches, hospital channels, and pharmacy channels, with direct routes further segmented into app stores and company websites that favor rapid consumer access. Pricing model segmentation spans licensing, pay-per-use, and subscription options, where subscription variants can be annual or monthly and influence lifetime value calculations and retention strategies. Deployment models bifurcate into cloud and on-premise, shaping integration complexity, data governance, and total cost of ownership. When combined, these segmentation vectors form a matrix that informs product positioning, clinical evidence generation, and commercial tactics tailored to each stakeholder cohort.

Comparative regional dynamics and practical implications for commercialization with tailored approaches for the Americas, EMEA, and Asia-Pacific markets

Regional dynamics create differentiated regulatory, reimbursement, and adoption environments that influence strategic priorities. In the Americas, market drivers emphasize payer engagement, employer-sponsored health programs, and a technology-literate patient population that values mobile and cloud-delivered interventions. Regulatory clarity in some jurisdictions supports defined pathways for clinical validation and reimbursement, but regional heterogeneity in state- and payer-level policies necessitates focused evidence generation aligned with local decision-makers.

Europe, Middle East & Africa features a mosaic of reimbursement landscapes and regulatory regimes where centralized and national-level health authorities play significant roles. Success in this region often requires interoperability with diverse electronic health record systems, multilingual user experiences, and nuanced pricing strategies to reflect public healthcare procurement processes. Moreover, regional privacy frameworks and data residency concerns can favor on-premise or hybrid deployment models, particularly for enterprise-grade solutions.

Asia-Pacific presents accelerated adoption potential driven by digital-first populations and large-scale public health initiatives, coupled with growing investment in local manufacturing that can mitigate tariff effects. However, fragmented regulatory frameworks and variable payer models require adaptable commercialization approaches and strong local partnerships. Across all regions, partnerships with healthcare providers, payers, and distribution channels remain essential to translate clinical evidence into funded adoption and sustained utilization.

Competitive strategies and partnership plays that differentiate leaders through clinical validation, interoperability, and adaptive commercial models across channels

Competitive behavior among leading companies is shaped by strategies that emphasize clinical validation, platform extensibility, and strategic partnerships across healthcare ecosystems. Market leaders prioritize randomized controlled trials and real-world evidence generation to meet payer and provider expectations, while also investing in interoperability and APIs that enable integration with electronic health records and remote monitoring systems. Partnerships with device manufacturers, sensor suppliers, and specialty clinics accelerate route-to-market for condition-specific solutions and support bundled care offerings.

Mergers, alliances, and licensing agreements are common approaches to address capability gaps in areas such as virtual reality content, advanced analytics, and on-the-ground clinical distribution. Companies focused on subscription and outcome-based pricing are collaborating more closely with payers and employers to create value-based contracts tied to clinical endpoints and utilization metrics. Meanwhile, firms that maintain flexible deployment options-cloud, on-premise, and hybrid-tend to capture enterprise accounts that prioritize data governance and system interoperability.

Smaller innovators often concentrate on niche therapeutic areas and differentiated delivery modes, leveraging direct distribution through app stores and targeted partnerships to achieve scale. Across the competitive landscape, successful companies combine strong clinical evidence, user-centered design, and commercial models that reflect the procurement preferences of employers, healthcare providers, and payers, while maintaining agility to adapt to tariff and regulatory shifts.

Practical strategic imperatives and prioritized actions for developers and enterprise stakeholders to accelerate adoption and protect margins amid evolving market conditions

Industry leaders should pursue a set of actionable priorities that align product development, evidence generation, and commercial execution. First, invest in robust clinical programs that include randomized trials and pragmatic real-world studies tailored to specific therapeutic segments such as cardiovascular subtypes, diabetes cohorts, neurological indications, oncology adjuncts, and respiratory conditions. Second, architect solutions for modular deployment across cloud and on-premise models to meet diverse enterprise requirements for data sovereignty and latency-sensitive workflows.

Third, prioritize platform interoperability and sensor-agnostic remote monitoring to reduce dependency on proprietary hardware and to mitigate exposure to tariff-induced cost fluctuations. Fourth, adopt flexible commercial strategies including subscription tiers and outcome-based contracts that reflect purchaser risk preferences and support long-term engagement. Fifth, cultivate strategic partnerships with device manufacturers, healthcare providers, employers, and payers to enable bundled care propositions and smoother pathways to reimbursement.

Finally, develop region-specific go-to-market plans for the Americas, Europe, Middle East & Africa, and Asia-Pacific that account for regulatory nuance, procurement practices, and patient engagement behaviors. Executing these priorities will require cross-functional coordination between clinical teams, product management, regulatory affairs, and commercial leaders to translate evidence into adoption and sustainable revenue streams.

Transparent mixed-methods research approach combining secondary synthesis and primary stakeholder validation to produce actionable and reproducible strategic insights

This research is grounded in a mixed-methods approach that integrates comprehensive secondary research with primary stakeholder engagements to validate findings and contextualize trends. Secondary analysis synthesized regulatory guidance, peer-reviewed clinical literature, technology capability reports, and publicly disclosed partnership and product announcements to map the evolving landscape. Primary research included structured interviews with clinicians, payers, employer health program managers, technology architects, and company executives to surface adoption drivers, procurement pain points, and evidence expectations.

Segmentation frameworks were developed by mapping therapeutic areas, delivery modes, end users, applications, distribution channels, pricing models, and deployment preferences to observed market behaviors. Where possible, cross-validation techniques were applied to reconcile discrepancies between primary insights and secondary sources, and scenario analysis was used to assess the potential impacts of macroeconomic variables such as tariff changes and supply chain disruptions. Limitations of the methodology include evolving regulatory actions and proprietary commercial agreements that may not yet be publicly visible, and therefore findings emphasize directional insights and actionable strategies rather than definitive commercial forecasts.

Transparency in assumptions and a clear audit trail of sources were maintained throughout the research process to support reproducibility and client-specific tailoring of the final deliverables.

Consolidated conclusion emphasizing clinical validation interoperability and commercial agility as the essential pillars for sustainable growth in digital therapeutics

Digital therapeutics now occupy a strategic intersection of clinical care and software innovation, offering scalable, evidence-based interventions across a widening set of therapeutic areas and delivery modes. The sector's near-term trajectory will be shaped by the ability of companies to demonstrate clinical outcomes, align commercial models with purchaser expectations, and adapt to macroeconomic influences such as tariffs that affect hardware-dependent solutions. Integration with clinical workflows, interoperability, and a focus on real-world evidence are central to converting pilot implementations into funded, large-scale programs.

Moreover, regional differences in regulation, reimbursement, and adoption behavior require tailored go-to-market approaches that respect local procurement norms while leveraging platform-level efficiencies. Competitive advantage will accrue to organizations that combine rigorous clinical validation with flexible deployment strategies, strategic partnerships, and pricing models that share risk and reward with payers and providers. In sum, success in digital therapeutics depends on an orchestration of clinical credibility, technical interoperability, and commercial ingenuity that together enable measurable patient impact and sustainable business models.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Digital Therapeutics Market, by Product Type

  • 8.1. Non-Prescription / Over-the-Counter (OTC) Digital Therapeutics
  • 8.2. Prescription Digital Therapeutics (PDTx)

9. Digital Therapeutics Market, by Therapy Area

  • 9.1. Diabetes Management
  • 9.2. Neurological Disorders
    • 9.2.1. Depression
    • 9.2.2. Anxiety Disorders
    • 9.2.3. Schizophrenia
    • 9.2.4. Epilepsy
    • 9.2.5. Multiple Sclerosis
  • 9.3. Obesity & Weight Management
  • 9.4. Chronic Respiratory Diseases
  • 9.5. Cardiovascular Diseases
  • 9.6. Mental & Behavioral Health
  • 9.7. Musculoskeletal Disorders / Pain Management
  • 9.8. Oncology Support Care
  • 9.9. Gastrointestinal Disorders
  • 9.10. Smoking Cessation
  • 9.11. Women's Health
  • 9.12. Rehabilitation & Physical Therapy
  • 9.13. Substance Use Disorders
  • 9.14. Sleep Disorders

10. Digital Therapeutics Market, by Platform

  • 10.1. Smartphone-Based Applications
  • 10.2. Wearable Device-Integrated DTx
  • 10.3. AI/ML-Based Digital Therapies
  • 10.4. Virtual Reality (VR)-Based DTx
  • 10.5. Digital Monitoring + Feedback Systems
  • 10.6. Web-Based / Cross-Platform Therapeutics

11. Digital Therapeutics Market, by Channel Type

  • 11.1. Patients / Direct-to-Consumer (D2C)
  • 11.2. Healthcare Providers (Hospitals & Clinics)
  • 11.3. Employers / Corporate Wellness Programs
  • 11.4. Pharmaceutical Partnerships
  • 11.5. Government & Public Health Systems

12. Digital Therapeutics Market, by End User

  • 12.1. Patients
  • 12.2. Healthcare Providers
  • 12.3. Employers & Corporate Wellness
  • 12.4. Caregivers & Rehabilitation Centers

13. Digital Therapeutics Market, by Deployment Mode

  • 13.1. Cloud-Based
  • 13.2. On-Premise
  • 13.3. Hybrid Deployment

14. Digital Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Digital Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Digital Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Digital Therapeutics Market

18. China Digital Therapeutics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2024
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2024
  • 19.3. Product Portfolio Analysis, 2024
  • 19.4. Benchmarking Analysis, 2024
  • 19.5. Abbott Laboratories
  • 19.6. F. Hoffmann-La Roche Ltd
  • 19.7. Noom, Inc.
  • 19.8. Novartis AG
  • 19.9. Novo Nordisk A/S
  • 19.10. Omada Health, Inc.
  • 19.11. Otsuka Holdings Co., Ltd.
  • 19.12. ResMed, Inc.
  • 19.13. Teladoc Health, Inc.
  • 19.14. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIGITAL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL DIGITAL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY NON-PRESCRIPTION / OVER-THE-COUNTER (OTC) DIGITAL THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY NON-PRESCRIPTION / OVER-THE-COUNTER (OTC) DIGITAL THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY NON-PRESCRIPTION / OVER-THE-COUNTER (OTC) DIGITAL THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DIGITAL THERAPEUTICS (PDTX), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DIGITAL THERAPEUTICS (PDTX), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DIGITAL THERAPEUTICS (PDTX), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY DEPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY DEPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY DEPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY ANXIETY DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY ANXIETY DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY ANXIETY DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SCHIZOPHRENIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SCHIZOPHRENIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY OBESITY & WEIGHT MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY OBESITY & WEIGHT MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY OBESITY & WEIGHT MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CHRONIC RESPIRATORY DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CHRONIC RESPIRATORY DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CHRONIC RESPIRATORY DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY MENTAL & BEHAVIORAL HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY MENTAL & BEHAVIORAL HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY MENTAL & BEHAVIORAL HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY MUSCULOSKELETAL DISORDERS / PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY MUSCULOSKELETAL DISORDERS / PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY MUSCULOSKELETAL DISORDERS / PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY ONCOLOGY SUPPORT CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY ONCOLOGY SUPPORT CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY ONCOLOGY SUPPORT CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SMOKING CESSATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SMOKING CESSATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SMOKING CESSATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY WOMEN'S HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY WOMEN'S HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY WOMEN'S HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY REHABILITATION & PHYSICAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY REHABILITATION & PHYSICAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY REHABILITATION & PHYSICAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SUBSTANCE USE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SUBSTANCE USE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SUBSTANCE USE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SLEEP DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SLEEP DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SLEEP DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SMARTPHONE-BASED APPLICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SMARTPHONE-BASED APPLICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY SMARTPHONE-BASED APPLICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY WEARABLE DEVICE-INTEGRATED DTX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY WEARABLE DEVICE-INTEGRATED DTX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY WEARABLE DEVICE-INTEGRATED DTX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY AI/ML-BASED DIGITAL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY AI/ML-BASED DIGITAL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY AI/ML-BASED DIGITAL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY VIRTUAL REALITY (VR)-BASED DTX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY VIRTUAL REALITY (VR)-BASED DTX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY VIRTUAL REALITY (VR)-BASED DTX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY DIGITAL MONITORING + FEEDBACK SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY DIGITAL MONITORING + FEEDBACK SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY DIGITAL MONITORING + FEEDBACK SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY WEB-BASED / CROSS-PLATFORM THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY WEB-BASED / CROSS-PLATFORM THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY WEB-BASED / CROSS-PLATFORM THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PATIENTS / DIRECT-TO-CONSUMER (D2C), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PATIENTS / DIRECT-TO-CONSUMER (D2C), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PATIENTS / DIRECT-TO-CONSUMER (D2C), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY HEALTHCARE PROVIDERS (HOSPITALS & CLINICS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY HEALTHCARE PROVIDERS (HOSPITALS & CLINICS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY HEALTHCARE PROVIDERS (HOSPITALS & CLINICS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY EMPLOYERS / CORPORATE WELLNESS PROGRAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY EMPLOYERS / CORPORATE WELLNESS PROGRAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY EMPLOYERS / CORPORATE WELLNESS PROGRAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL PARTNERSHIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL PARTNERSHIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL PARTNERSHIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY HEALTHCARE PROVIDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY HEALTHCARE PROVIDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY EMPLOYERS & CORPORATE WELLNESS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY EMPLOYERS & CORPORATE WELLNESS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY EMPLOYERS & CORPORATE WELLNESS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CAREGIVERS & REHABILITATION CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CAREGIVERS & REHABILITATION CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CAREGIVERS & REHABILITATION CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CLOUD-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CLOUD-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY CLOUD-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY ON-PREMISE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY ON-PREMISE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY ON-PREMISE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY HYBRID DEPLOYMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY HYBRID DEPLOYMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY HYBRID DEPLOYMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS DIGITAL THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 200. GCC DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GCC DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. GCC DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 203. GCC DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 204. GCC DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 205. GCC DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. GCC DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. GCC DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 224. G7 DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. G7 DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. G7 DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 227. G7 DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 228. G7 DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 229. G7 DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. G7 DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. G7 DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 232. NATO DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. NATO DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. NATO DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 235. NATO DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 236. NATO DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 237. NATO DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. NATO DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. NATO DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA DIGITAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA DIGITAL THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA DIGITAL THERAPEUTICS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA DIGITAL THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA DIGITAL THERAPEUTICS MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA DIGITAL THERAPEUTICS MARKET SIZE, BY CHANNEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA DIGITAL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA DIGITAL THERAPEUTICS MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)